<DOC>
	<DOCNO>NCT01224405</DOCNO>
	<brief_summary>The study include recruitment patient advanced prostate cancer resistant chemical castration This multicenter prospective trial randomize phase III</brief_summary>
	<brief_title>Prostate Cancer , Androgen Deprivation Withdrawal Intermittent Chemotherapy</brief_title>
	<detailed_description>The study include recruitment patient advanced prostate cancer resistant chemical castration This multicenter prospective trial randomize phase III This study design include double randomizzzazione aim generally demonstrate non-inferiority term survival suspension dell'ormonoterapia versus maintenance / administration intermittent versus continuous administration chemotherapy patient prostate cancer resistant chemical castration I start line chemotherapy Docetaxel .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>1. age 18 year , 2. histologically document adenocarcinoma prostate , 3. write informed consent study , 4 . Castrate resistant metastatic prostate cancer presence castrate level testosterone ( &lt; 50 ng/ml ) eligible docetaxel chemotherapy . The condition castrate resistant prostate cancer define either documentation new metastasis PSA increase 50 % increase 25 % low PSA value previous hormone therapy case disease response stabilization previous hormone therapy , respectively . Absolute PSA increase great 5 ng/ml , 5. elevate PSA level must document within 4 week initiate docetaxel chemotherapy , 6. 4 week since major surgery fully recover , 7. 4 week since prior radiation toxicity attributable radiation resolve grade 1 less , 8. 8 week since last dose strontium samarium , 9 . ECOG Performance Status than/equal 2 , 10. life expectancy &gt; 6 month , 11. require initial laboratory value : absolute neutrophil count &gt; 1500/ul Platelets &gt; 100,000/ul. , Hemoglobin &gt; 8.0 g/dl , Creatinine , SGOT , SGPT le 2.0 X upper limit normal , Bilirubin less than/equal upper limit normal ( ULN ) . 12 . Appropriate patient compliance 1 . Patients increase serum PSA level negative bone scan CT scan . 2 . Prior systemic chemotherapy prostate cancer . Prior neoadjuvant adjuvant chemotherapy permit evidence disease relapse within 12 month last dose chemotherapy , 3 . Peripheral neuropathy &gt; grade 1 , 4. myocardial infarction significant change anginal pattern within last 6 month , symptomatic congestive heart failure ( NYHA Class III high ) uncontrolled cardiac arrhythmia , 5. patient history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 , 6. poorly control diabetes ( fast blood glucose &gt; 250 ) despite optimization medical therapy , peptic ulcer contraindication steroid therapy , 7. previous history malignant disease exception non melanoma skin cancer curatively treat , 8. significant neurologic psychiatric disease prevent patient give valid inform consent , 9. brain metastasis , 10. prisoner status 11. patient immune deficiency increase risk lethal infection treat marrowsuppressive therapy , HIVpositive patient receive combination antiretroviral therapy exclude .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>